@article{b2510f5316b843ab9ed32e7148cd6af9,
title = "Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients",
abstract = "Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.",
keywords = "Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Endostatins, Female, Humans, Middle Aged, Neovascularization, Pathologic, Ovarian Neoplasms, Pyrazoles, Quality of Life, Recurrence, Sulfonamides, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Endostatins, Female, Humans, Middle Aged, Neovascularization, Pathologic, Ovarian Neoplasms, Pyrazoles, Quality of Life, Recurrence, Sulfonamides, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A",
author = "Francesco Legge and Amelia Paglia and Marco D'Asta and Gilda Fuoco and Giovanni Scambia and Ferrandina, {Maria Gabriella}",
year = "2011",
doi = "10.1186/1471-2407-11-214",
language = "English",
volume = "11",
pages = "214--214",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BIOMED CENTRAL LTD, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON, ENGLAND, W1T 4LB",
}